Skip to main content

Authorized Nuclear Pharmacist: Training & Role

By Troy Zhou, PhD, DABR, DABSNM
• 16 min read

The authorized nuclear pharmacist is the person a radioactive-material license names to prepare and supervise the preparation of radiopharmaceuticals. Behind almost every imaging dose a patient receives is an ANP who received the generator, eluted it, compounded the kit, assayed the dose, ran the quality-control tests, and documented that the product met its limits before release.

Nuclear medicine depends on a supply chain that produces a sterile, short-lived radioactive drug on a tight clock and releases it only after a defined set of safety and purity checks. The authorized nuclear pharmacist (ANP) sits at the center of that chain. The role is not informal: it is defined by specific training-and-experience requirements in 10 CFR 35.55, by quality-control duties that keep a generator eluate and a compounded dose within limits, and by the commercial radiopharmacy framework that supplies most of the field 1, 4, 6.

This guide explains the two pathways to becoming an ANP, the radiation-safety and QC responsibilities the role carries, the commercial and in-house licensing context, and the standards that govern it. DRPS supports nuclear medicine and radiopharmacy programs through its radioactive material license support and radiation safety officer services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Introduction

A radiopharmaceutical is a drug and a radioactive material at once, so its preparation falls under both pharmacy practice and radioactive-material licensing. The person who bridges those worlds is the authorized nuclear pharmacist. On a commercial nuclear pharmacy license, the ANP is the individual authorized to prepare and supervise the preparation of radioactive drugs for medical use; on a medical-use license, an ANP (or an authorized user physician) may be named for the same preparation activities 1, 6.

The ANP designation is a radiation-safety credential, not merely a job title. It certifies that the pharmacist has the training and experience to handle unsealed byproduct material safely, to run the quality-control tests that gate release, and to supervise others doing the same work. For the parallel credential on the physician and medical-physicist side, see authorized user and medical physicist training and experience.

Topic Explanation

What the ANP is authorized to do

An ANP named on a license may prepare radiopharmaceuticals and supervise their preparation. In practice this spans a defined set of operations:

  • receiving and surveying incoming radionuclides, generators, and kits;
  • eluting Mo-99/Tc-99m and other generators;
  • compounding and dispensing patient and unit doses;
  • performing and documenting dose calibrator QC and product quality-control tests;
  • managing radioactive waste, contamination surveys, and spill response in the pharmacy;
  • supervising technicians and other staff who prepare doses under the ANP's responsibility.

Those operations take place in a shielded preparation area — the hot lab — whose design and workflow the ANP works within daily. For that physical environment, see nuclear medicine hot lab design, and for the aseptic practices that protect the product, see radiopharmacy aseptic technique and QC.

The two qualification pathways

10 CFR 35.55 defines two routes to ANP status 2. The table summarizes them.

Pathway What it requires Key feature
Board certification Certification by a specialty board whose certification process the NRC or an Agreement State has recognized The recognized board's program is deemed to meet the training-and-experience standard
Alternate (training + experience) 700 hours in a structured educational program, including at least 200 hours of classroom and laboratory training, plus supervised practical experience in nuclear pharmacy Requires a written preceptor attestation of competence

Under either pathway, the regulation also requires a preceptor attestation: a preceptor authorized nuclear pharmacist must provide written certification that the individual has satisfactorily completed the requirements and is competent to independently perform the radiation-safety-related duties of an ANP 2. The classroom-and-laboratory component covers areas such as radiation physics and instrumentation, radiation protection, mathematics of radioactivity, radiation biology, and radiopharmaceutical chemistry; the supervised component is hands-on practice under a qualified ANP.

Named on the license

Being qualified is not the same as being authorized at a given facility. An ANP must be named on, or added by amendment to, the radioactive-material license (or working under a commercial nuclear pharmacy's authorization) before practicing there. Adding an ANP to a medical-use license is handled through the license amendment process; see NRC medical license amendments and the broader NRC license guide.

Key Technical Principles

Quality control is the heart of the role

The ANP's radiation-safety value is concentrated in the quality-control tests that gate release of a dose. Two are worth working through quantitatively.

Decay correction for dispensing. A radiopharmacy calibrates each dose to deliver a stated activity at a stated calibration time. Because activity decays continuously, the activity to draw at an earlier assay time must be decay-corrected:

For Tc-99m, hours, so 10. To deliver 740 MBq (20 mCi) at a 10:00 calibration time, a dose assayed four hours earlier at 06:00 must contain:

so the pharmacist draws about 1174 MBq (31.7 mCi) at 06:00 for it to decay to 740 MBq by 10:00. Getting this correction right is a patient-dose and a radiation-safety matter.

Molybdenum-99 breakthrough. Each Mo-99/Tc-99m generator eluate must be tested for Mo-99 contamination. Under 10 CFR 35.204, an administered Tc-99m radiopharmaceutical may contain no more than 0.15 µCi of Mo-99 per mCi of Tc-99m (0.15 kBq/MBq) 3. Critically, the limit applies at the time of administration, and the contamination ratio changes with time because the two radionuclides decay at very different rates. The ratio evolves as:

Because Mo-99 ( h) decays far more slowly than Tc-99m ( h), the exponent is positive and the ratio rises over the day 10. Suppose an eluate measures µCi/mCi at elution. After 6 hours, Tc-99m has decayed by a factor while Mo-99 has decayed by only , so:

An eluate that passed comfortably at elution reaches the limit six hours later. This is why the ANP measures each eluate and interprets the result against the time of administration, not just the time of elution.

Generator eluate contamination limits

The Mo-99 limit is one of three radionuclidic-purity limits the pharmacy applies to generator eluates 3.

Contaminant / parent Limit Applies to
Mo-99 in Tc-99m 0.15 µCi Mo-99 per mCi Tc-99m Each Mo-99/Tc-99m generator eluate
Sr-82 in Rb-82 0.02 µCi Sr-82 per mCi Rb-82 Rb-82 generator eluate (cardiac PET)
Sr-85 in Rb-82 0.2 µCi Sr-85 per mCi Rb-82 Rb-82 generator eluate (cardiac PET)

Measurements must be recorded, and any eluate exceeding a limit must be handled under the reporting and recordkeeping provisions of Part 35 3. The instrument that underpins these measurements — the dose calibrator — has its own QC program; see dose calibrator quality control.

Clinical Impact

Supply, safety, and continuity

Most clinical nuclear medicine does not operate its own cyclotron or compound every dose in-house; it relies on commercial nuclear pharmacies that deliver unit doses. Those pharmacies are licensed under the commercial distribution framework and must have an ANP to prepare or supervise preparation of the drugs they ship 4, 6. The ANP is therefore a point of both safety and continuity: a pharmacy without a qualified, named ANP cannot lawfully prepare doses, which directly affects a department's ability to image patients.

Protecting the patient and the worker

The ANP's QC gates protect the patient from an out-of-specification dose — wrong activity, radiochemical impurity, or radionuclidic contamination such as excess Mo-99 — and protect the worker through contamination control, shielding, and survey practices in the hot lab. A disciplined ANP program reduces medical-event risk and occupational dose simultaneously 1, 7.

Supervision multiplies the role

Because an ANP may supervise others, one qualified pharmacist can enable a team of technicians to prepare doses safely, provided the supervision is real and the ANP retains responsibility. This is how a busy pharmacy scales without diluting the safety credential 6.

Practical Optimization Tips

1. Confirm the qualification pathway before relying on it

Verify whether an ANP qualifies by recognized board certification or by the 700-hour alternate pathway, and keep the preceptor attestation and training records on file for inspection 2.

2. Get the ANP named on the license

Qualification does not authorize practice at a facility until the ANP is named on, or added by amendment to, the license. Track this actively when staff change.

3. Treat the Mo-99 limit as a time-of-administration test

Interpret each eluate's breakthrough against the time the dose will be administered, not elution, and account for the rising ratio over the day 3.

4. Keep QC records contemporaneous and complete

Dose calibrator constancy, linearity, accuracy, and geometry; eluate breakthrough; and radiochemical purity results should be recorded as they are performed, with the reviewing ANP identified.

5. Separate the ANP and RSO roles deliberately

If one person holds both the ANP and RSO roles, document each qualification and authorization separately; do not assume one credential satisfies the other. See the radiation safety officer role.

Common pitfalls to avoid

  • Assuming a licensed pharmacist is automatically an ANP. ANP status requires the specific 35.55 pathway and a preceptor attestation.
  • Confusing qualification with authorization. An ANP must be named on the license to practice there.
  • Testing Mo-99 only at elution. The limit is a time-of-administration limit, and the ratio grows.
  • Letting supervision become nominal. Supervised preparation requires real, responsible oversight by the ANP.
  • Treating ANP and RSO as interchangeable. The roles and their requirements are distinct.

Regulatory Considerations

The ANP role sits inside the NRC or Agreement State framework for the medical use and commercial distribution of byproduct material, supported by USP pharmacy-practice standards. The relevant frameworks are:

  • 10 CFR Part 35, Medical Use of Byproduct Material, which defines the ANP and the preparation of radiopharmaceuticals, with 10 CFR 35.55 setting the training-and-experience requirements 1, 2.
  • 10 CFR 35.204, which sets the Mo-99, Sr-82, and Sr-85 eluate contamination limits and the associated testing 3.
  • 10 CFR Part 32, which governs the commercial manufacture, preparation, and distribution of radioactive drugs, the basis for commercial nuclear pharmacy licensing 4.
  • 10 CFR Part 20, Standards for Protection Against Radiation, which sets the occupational and public dose limits the pharmacy's radiation-protection program must meet 5.
  • NRC NUREG-1556, Volume 13, program-specific guidance for commercial radiopharmacy licenses, including the ANP 6.
  • USP General Chapter <825>, Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging, the pharmacy-practice standard for handling radiopharmaceuticals, whose official date is December 1, 2020 7. General sterile-compounding practice is addressed in USP General Chapter <797> 8.

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use and nuclear pharmacies under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and recognizes its ANP's credentials. DRPS supports these programs through radioactive material license support, RSO consulting, and medical physics consulting.

Frequently Asked Questions (FAQs)

What is an authorized nuclear pharmacist?

An authorized nuclear pharmacist (ANP) is a pharmacist named on a radioactive-material license who is qualified to prepare, and to supervise the preparation of, radiopharmaceuticals for medical use. The ANP is the person a commercial nuclear pharmacy or a medical licensee relies on to receive generators and radionuclides, compound and dispense doses, perform the required quality-control tests, and carry out the associated radiation-safety duties under the NRC or Agreement State framework.

How does a pharmacist become an authorized nuclear pharmacist?

There are two pathways under 10 CFR 35.55. One is certification by a specialty board that the NRC or an Agreement State has recognized. The other is an alternate pathway of 700 hours in a structured educational program — at least 200 hours of classroom and laboratory training plus supervised practical experience in a nuclear pharmacy — followed by a written attestation from a preceptor authorized nuclear pharmacist that the individual is competent to independently perform the radiation-safety duties of an ANP.

What quality-control tests does an ANP perform?

Core nuclear pharmacy QC includes dose calibrator constancy, linearity, accuracy, and geometry; molybdenum-99 breakthrough testing of each Mo-99/Tc-99m generator eluate; radiochemical purity testing of compounded radiopharmaceuticals; and documentation of each test. These confirm that the activity dispensed and the radionuclidic and radiochemical purity of the product meet limits before release.

What is the molybdenum-99 breakthrough limit?

Under 10 CFR 35.204, a Tc-99m radiopharmaceutical administered to a patient may contain no more than 0.15 microcurie of Mo-99 per millicurie of Tc-99m (0.15 kBq per MBq). The limit is evaluated at the time of administration, and because Mo-99 decays much more slowly than Tc-99m, the ratio rises over the day, so each eluate is measured and borderline eluates can exceed the limit before use.

Is an ANP the same as a radiation safety officer?

No. The ANP is qualified to prepare and supervise radiopharmaceutical preparation and to perform the related radiation-safety and QC duties for those operations. The radiation safety officer (RSO) is responsible for the overall radiation protection program of the license. A single person may hold more than one role if separately qualified and named on the license, but the roles and their requirements are distinct.

What regulations and standards govern nuclear pharmacy practice?

In the United States, the medical use and preparation of radiopharmaceuticals is governed by NRC or Agreement State rules in 10 CFR Part 35, commercial distribution by 10 CFR Part 32, and radiation protection by 10 CFR Part 20, with NRC NUREG-1556 Volume 13 providing commercial radiopharmacy licensing guidance. Pharmacy-practice standards for preparing and compounding radiopharmaceuticals are set in USP General Chapter <825>.

Can someone who is not an ANP work in a nuclear pharmacy?

Yes, under the supervision of an authorized nuclear pharmacist. Technicians and other staff may prepare radiopharmaceuticals when an ANP directly supervises the work and takes responsibility for it, consistent with the license conditions and applicable NRC or Agreement State requirements.

Key Takeaways

  • The ANP prepares and supervises radiopharmaceutical preparation and performs the radiation-safety and QC duties that gate dose release.
  • Two pathways qualify an ANP under 10 CFR 35.55: recognized board certification, or a 700-hour alternate pathway (≥200 classroom/lab hours plus supervised experience) with a preceptor attestation.
  • Qualification is not authorization. An ANP must be named on the license to practice at a facility.
  • QC is quantitative. Decay correction and Mo-99 breakthrough are worked calculations, and the 0.15 µCi/mCi limit is a time-of-administration test on a ratio that rises over the day.
  • Commercial radiopharmacies depend on the ANP. Without a qualified, named ANP, a pharmacy cannot lawfully prepare doses.
  • ANP and RSO are distinct roles, even when one person holds both.

Conclusion

The authorized nuclear pharmacist is a quiet linchpin of nuclear medicine: the credential that lets a sterile, short-lived radioactive drug be prepared, tested, and released safely, day after day. The role is defined by concrete training-and-experience requirements, by quality-control tests that are genuinely quantitative, and by a licensing framework that ties the person to the facility.

For a radiation safety program, the practical message is to treat ANP qualification and authorization as separate steps, to keep the training, attestation, and QC records complete and contemporaneous, and to interpret the eluate limits against the time of administration. The medical physicist and RSO support the ANP by validating instrument QC, reviewing records, and keeping the program aligned with NRC or Agreement State requirements.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine facilities and radiopharmacy programs turn licensing and QC requirements into documented, defensible workflows. This can include radioactive material license support and amendments to name authorized nuclear pharmacists and users, hot lab design and survey review, dose calibrator and eluate-testing QC program review, radiation-protection program support, and inspection readiness.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware, through radioactive material license support, radiation safety officer consulting, and medical physics consulting.

Related Resources

References

  1. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
  2. U.S. Nuclear Regulatory Commission. 10 CFR 35.55: Training for an Authorized Nuclear Pharmacist. ecfr.gov
  3. U.S. Nuclear Regulatory Commission. 10 CFR 35.204: Permissible Molybdenum-99, Strontium-82, and Strontium-85 Concentrations. ecfr.gov
  4. U.S. Nuclear Regulatory Commission. 10 CFR Part 32: Specific Domestic Licenses to Manufacture or Transfer Certain Items Containing Byproduct Material. ecfr.gov
  5. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
  6. U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 13: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Commercial Radiopharmacy Licenses. nrc.gov
  7. United States Pharmacopeia. USP General Chapter <825>: Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging. Official December 1, 2020. usp.org
  8. United States Pharmacopeia. USP General Chapter <797>: Pharmaceutical Compounding — Sterile Preparations. usp.org
  9. Zanzonico P. Routine quality control of clinical nuclear medicine instrumentation: a brief review. J Nucl Med. 2008;49(7):1114-1131. doi:10.2967/jnumed.107.050203. PubMed
  10. International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org
  • NRC Part 35 Recordkeeping Requirements

    NRC 10 CFR Part 35 recordkeeping: which records medical-use licensees must keep, exact retention periods, Part 20 cross-references, and how to survive inspection.

  • Shipping Radioactive Material: DOT 49 CFR

    Package types, White-I/Yellow-II/Yellow-III labels, Transport Index, dose and contamination limits, hazmat training, and receiving surveys under 10 CFR 20.

  • Accelerator-Produced and NARM Byproduct Material

    How the 2005 Energy Policy Act and NRC's 2007 rule made accelerator-produced and NARM material federal byproduct material—and what that means for PET isotopes, licensing, and radiation safety.